Coeptis Therapeutics, Inc.
COEP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | -$1 | -$1 | -$1 | $0 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $2 | $7 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $14 |
| SG&A Expenses | $7 | $14 | $33 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $20 | $33 | $14 |
| Operating Income | -$10 | -$21 | -$34 | -$14 |
| % Margin | – | – | – | -18,727.9% |
| Other Income/Exp. Net | -$1 | $0 | -$3 | $1 |
| Pre-Tax Income | -$11 | -$21 | -$38 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$21 | -$38 | -$13 |
| % Margin | – | – | – | -17,932.4% |
| EPS | -5.65 | -0.83 | -2.87 | -13.16 |
| % Growth | -580.7% | 71.1% | 78.2% | – |
| EPS Diluted | -5.65 | -0.83 | -2.87 | -13.16 |
| Weighted Avg Shares Out | 2 | 26 | 14 | 1 |
| Weighted Avg Shares Out Dil | 2 | 26 | 14 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$9 | -$20 | -$36 | -$13 |
| % Margin | – | – | – | -17,086.3% |